XML 74 R11.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Restructuring Charges
6 Months Ended
Dec. 31, 2019
Restructuring Charges  
Restructuring Charges

Note 4.  Restructuring Charges

Cody Restructuring Program

On June 29, 2018, the Company announced a restructuring plan with respect to Cody Labs (the “Cody Restructuring Plan”).  The plan focused on a more select set of opportunities which resulted in streamlined operations, improved efficiencies and a reduced cost structure.  The Company incurred approximately $2.5 million of severance and employee-related costs under this plan. The restructuring activities under the Cody Restructuring Program were completed as of June  30, 2019.

The credits associated with the Cody Restructuring Plan included in restructuring credits during the three and six months ended December 31, 2018 were as follows:

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Six Months Ended

 

(In thousands)

    

December 31, 2018

    

December 31, 2018

 

Employee separation costs (credits)

 

$

(640)

 

$

(496)

 

Facility closure costs

 

 

 —

 

 

 —

 

Total

 

$

(640)

 

$

(496)

 

 

A reconciliation of the changes in restructuring liabilities associated with the Cody Restructuring Plan from June 30, 2019 through December 31, 2019 is set forth in the following table:

 

 

 

 

 

 

 

 

 

 

 

 

    

Employee

    

Facility Closure

    

 

(In thousands)

    

Separation Costs

    

Costs

    

Total

Balance at June 30, 2019

 

$

108

 

$

 —

 

$

108

Restructuring Charges

 

 

 —

 

 

 —

 

 

 —

Payments

 

 

(108)

 

 

 —

 

 

(108)

Balance at December 31, 2019

 

$

 —

 

 

 —

 

$

 —

 

Cody API Restructuring Plan

In September 2018, the Company approved a plan to sell the active pharmaceutical ingredient manufacturing distribution business of Cody Labs (the “Cody API business”).  The Company was unable to sell the Cody API business as an ongoing operation and intends to sell the equipment and real estate utilized by the Cody API business and to have Cody Labs cease all operations.  In June 2019, the Company approved the Cody API Restructuring Plan.  In connection with the Cody API Restructuring Plan, there has been a reduction of almost 70 positions at Cody Labs.  The restructuring activities under the Cody API Restructuring Plan are substantially complete as of December 31, 2019.  In the first quarter of Fiscal 2020, the Company completed the sale of a portion of the equipment associated with the Cody API business for $2.0 million. In the second quarter of Fiscal 2020, the Company signed a two-year agreement to lease a portion of the real estate.

The costs to implement the Cody API Restructuring Plan total approximately $6.0 million, including approximately $3.5 million of severance and employee-related costs and approximately $2.0 million of contract termination costs, as well as approximately $0.5 million of costs to be incurred in connection with moving equipment and other property to other Company-owned facilities that were originally anticipated to be incurred in connection with the Cody Restructuring Plan announced in June 2018.

The expenses associated with the Cody API Restructuring Plan included in restructuring expenses during the three and six months ended December 31, 2019 were as follows:

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Six Months Ended

 

 

    

December 31, 

 

December 31, 

 

(In thousands)

 

2019

 

2019

 

Employee separation costs

 

$

192

 

$

1,084

 

Facility closure costs

 

 

 —

 

 

496

 

Total

 

$

192

 

$

1,580

 

 

A reconciliation of the changes in restructuring liabilities associated with the Cody API Restructuring Plan from June 30, 2019 through December 31, 2019 is set forth in the following table:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Employee

 

Contract

 

Facility

 

 

 

 

 

Separation

 

Termination

 

Closure

 

 

 

(In thousands)

    

Costs

    

Costs

    

Costs

    

Total

Balance at June 30, 2019

 

$

2,207

 

$

 

$

 

$

2,207

Restructuring Charges

 

 

1,084

 

 

 —

 

 

496

 

 

1,580

Payments

 

 

(2,776)

 

 

 —

 

 

(496)

 

 

(3,272)

Balance at December 31, 2019

 

$

515

 

$

 —

 

 

 —

 

$

515

 

2016 Restructuring Program

On February 1, 2016, in connection with the acquisition of Kremers Urban Pharmaceuticals Inc.("KUPI "), the Company announced a plan related to the future integration of KUPI and the Company’s operations (the “2016 Restructuring Program”). The plan focused on the closure of KUPI’s corporate functions and the consolidation of manufacturing, sales, research and development and distribution functions. The restructuring activities under the 2016 Restructuring Program were completed as of March 31, 2019. The Company incurred an aggregate of approximately $21.0 million in restructuring charges for actions that have been announced or communicated since the 2016 Restructuring Program began.  Of this amount, approximately $11.0 million related to employee separation costs, approximately $1.0 million relates to contract termination costs and approximately $9.0 million related to facility closure costs and other actions.

The expenses associated with the restructuring program included in restructuring expenses during the three and six months ended December 31, 2018 were as follows:

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Six Months Ended

 

 

December 31, 

 

December 31, 

(In thousands)

    

2018

    

2018

Employee separation costs

 

$

293

 

$

707

Facility closure costs

 

 

560

 

 

1,024

Total

 

$

853

 

$

1,731